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1 |  INTRODUCTION
To aid in prompt diagnosis of acute promyelocytic leukemia, 
flow cytometry is routinely performed to demonstrate the 
triad of weak/absent CD34, negative HLA-DR expression, 
and positivity to CD117. We report a case of 34-year-old fe-
male whose immunophenotyping results showed positivity to 
HLA-DR, CD34 and CD 117.
Acute promyelocytic leukemia (APL) with t(15;17) 
(q22;q21)/PML-RARα is a subtype of acute myeloid leu-
kemia (AML) with distinct morphologic characteristics.1 It 
can become aggressive and life threatening if there is a delay 
in recognition of the clinical presentation and diagnosis. 
Patients can develop coagulopathy leading to bleeding dia-
thesis and death.2 However, due to improvement in diagnos-
tic modalities and early initiation of ALL-trans-retinoic acid 
(ATRA) and arsenic trioxide, the outcomes of dramatically 
improved. The definition of disease is through the detection 
of t(15;17) (q22;q21)/PML-RARα mutation, and this serves 
as the molecular basis of treatment with ATRA.3
The diagnosis of hematological malignancy especially 
in leukemia, after clinical history and physical examination, 
begins with performing complete blood count and review of 
peripheral smear. The classical morphology on peripheral 
smear of the abnormal promyelocytes reveals bilobed nucleus, 
abundant granules in the cytoplasm, presence of Auer rods, 
and faggot cells which is pathognomonic for APL.4 Although 
confirmation is through molecular studies, to aid in rapid di-
agnosis, flow cytometry has been widely used and extensively 
studied. Compared with other types of AML, the most consis-
tent immunophenotype in APL includes absent or weak CD34, 
absent HLA-DR (which belongs to human leukocyte antigen 
class II), and positive CD117.5 Other features in flow cytom-
etry that are commonly seen in APL include heterogeneity of 
high side scatter, absent, low-level, or less frequent expression 
of CD10, CD11a, CD11b, CD11c, CD18, CD45RO, CD105, 
and CD133.6,7 HLA-DR-positive APL is a rare entity and has 
been scarcely reported. Mendoza et al8 has described 45 cases 
of APL of which only two were HLA-DR-positive in which 
the clinical, morphological, and molecular characteristics were 
similar to HLA-DR negative APL.
Herein, we describe the case of a 34-year-old female who 
presented with clinical signs and symptoms of APL and 
immunophenotyping by flow cytometry analysis showed 
HLA-DR to be positive while PML-RARα mutation was also 
positive.
2 |  CASE REPORT
A 34-year-old female presented to the emergency department 
of Aga Khan University Karachi, Pakistan, with complaints 
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The triad of weak/absent CD34, negative HLA-DR expression, and positivity 
to CD117 is pathognomonic for the diagnosis of acute promyelocytic leukemia. 
However, in rare cases, strong positivity to HLD-DR and CD34 may be noted.
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of gingival bleeding, menorrhagia, and easy bruisability for 
one week. On examination, she had active oozing from gums 
and multiple, large bruises all over the body. There was no 
organomegaly. Baseline laboratory investigations showed 
Hb: 9.5  gm/dL, WBC: 21  ×  109/L, platelets: 13  ×  109/L. 
Peripheral blood film showed 75% abnormal promyelocytes 
with cytoplasm containing granules, Auer rods and faggot 
cells (Figure 1). Prothrombin time (PT) was > 170 seconds, 
INR  >  17, activated partial thromboplastin time (APTT) 
was 43  seconds, fibrinogen was 35  mg/dL, and d-Dimer 
was  >  30  mg/L FEU. Liver and renal function tests were 
within normal limits. Based on the findings of peripheral 
smear, immunophenotyping by flow cytometry (performed 
on BD FACSCantoTM analyzer, 8 color and 3 lasers) and 
molecular analysis of PML-RARα mutation was sent on pe-
ripheral blood. Bone marrow aspirate and trephine could not 
be performed at that time due to deranged coagulation pa-
rameters. Immunophenotype of the abnormal promyelocytes 
revealed positivity to CD4 (33%), CD13 (68%), CD33 (70%), 
cMPO (66%), HLA-DR (30%), CD117 (57%), CD34 (50%), 
CD36 (41%), and CD64 (66%) (Figure 2).
Due to the classical clinical and morphological find-
ings, the patient was started on ATRA (45mg/m2/day in 2 
divided doses) and prophylactic dexamethasone 10mg once 
a day while we awaited molecular results. In 48 hours, the 
molecular analysis confirmed the presence of PML-RARα 
mutation. Her INR at that time became <1.5 and samples for 
bone marrow aspirate and cytogenetic analysis were drawn. 
Bone marrow morphology showed diffuse infiltration with 
abnormal promyelocytes. These cells were large with con-
voluted cytoplasm containing reddish pink granules and 
Auer rods (Figure 3). Since she was in the high risk category 
(WBC > 10 × 109/L), induction with daunorubicin and cy-
tarabine (3 + 7 regimen) was started concomitantly while she 
received supportive care with 3 units of fresh frozen plasma 
(FFP) twice a day to keep INR less than 1.5 and D-Dimer less 
than 5 mg/L FEU. To maintain fibrinogen level of ≥200 mg/
dL, 10 units of cryoprecipitate were transfused routinely. She 
also received platelet transfusion to sustain platelet count of 
≥30 × 109/L. The WBC count after starting ATRA was grad-
ually increasing from 21 to 35 to 45 × 109/L at which point 
capsule Hydroxyurea 1gm once a day was added.
Four days after starting ATRA she developed hemopty-
sis, tachypnea (respiratory rate 35/min), tachycardia (heart 
rate 120/min) and required noninvasive ventilation to main-
tain oxygen saturation of ≥95%. A differential diagnosis of 
ATRA syndrome was made and the drug was stopped. Chest 
X-ray revealed airspace shadowing (Figure  4) bilaterally 
with pulmonary edema. After stopping ATRA and adequate 
diuresis, her condition improved in 12  hours though chest 
X-ray findings improved over 24 to 48  hours. ATRA has 
been restarted at 50% dose while blood count recovery was 
awaited. Subsequently she was discharged after 28  days of 
induction chemotherapy. Her day-28 bone marrow revealed 
trilineage hematopoiesis with less than 5% blast cells while 
PML-RARα mutation was not detected. At present she has 
completed two cycles consolidation chemotherapy and is re-
ceiving maintenance treatment. Her PML-RARα mutation at 
the end of consolidation chemotherapy was not detected as 
well.
3 |  DISCUSSION
Acute promyelocytic leukemia is characterized by clonal 
proliferation of abnormal promyelocytes. The World Health 
Organization's (WHO) classification recognizes the impor-
tance of genetic aberrations in the diagnosis and prognosti-
cation of AML and categorizes four unique groups of AML 
with recurrent chromosomal translocations out of which 
AML with t(15;17) is specific to APL. The others include 
AML with t(8;21) (q22;q22), AML with inv(16)(p13q22)/ 
t(16;16)(p13;q22) and AML with 11q23 abnormalities. 
These four entities currently constitute about 25%-30% of all 
cases of adult AML.9 Immunophenotyping by flow cytom-
etry has become an essential tool for the lineage determina-
tion of leukemic blast cells. Various myeloid markers such 
as CD33, CD13, MPO, CD117, CD64, CD133, etc, are well 
recognized and useful for the confirmation of AML.10
The antigen HLA-DR is normally expressed on myelo-
blasts and loses expression at the promyelocyte stage of the 
maturation process. The absence of HLA-DR positivity is 
considered to be highly suggestive of APL and is used to 
distinguish AML from APL. In various studies published 
F I G U R E  1  Peripheral blood film at 
(100×) showing abnormal promyelocytes 
and faggot cell
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before, HLA-DR expression has been reported with a range 
of 0%-9%11,12 of cases. The percentage of expression has 
also been variable in the studies reported, for example, Dong 
et al13 reported only one case of APL with strong HLA-DR 
expression (20% or more) while four cases had a weak 
HLA-DR expression (staining 5%-20% of cells). In our case, 
F I G U R E  2  Immunophenotyping by 
flow cytometry showing positivity to HLA-
DR and CD34. A, Screening tube showing 
positivity to MPO. B, HLA-DR positivity 
in combination with CD33, CD13. C, CD34 
positivity in combination with CD117
F I G U R E  3  Bone marrow aspirate 
(100×) showing abnormal promyelocytes 
with bilobed nuclei
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the HLA-DR expression was very strong (30%) which rarely 
has been reported in literature. Along with HLA-DR expres-
sion, she also had positivity for CD34 (50%), which follows 
the same pattern of expression as HLA-DR, that is, negative 
expression on abnormal promyelocytes. CD34 positivity has 
been sparsely reported previously. Foley et al14 has reported a 
cohort of 38 patients with APL, of which 32% of cases were 
CD34-positive and correlated with less differentiated APL 
blasts. In these patients, the incidence of early mortality is 
50%. There is significant correlation between CD34 positiv-
ity and raised WBC count at presentation. Our patient also 
had similar parameters of HLA-DR and CD34 expression 
along with WBC count of 21 x 109/L at presentation.
According to the National Comprehensive Cancer 
Network (NCCN) Guidelines, ATRA should be started be-
fore genetic confirmation in patients with clinical and patho-
logical features of APL because early initiation of ATRA 
may prevent the lethal complication of bleeding resulting 
from disseminated intravascular coagulation.15 Moreover, 
while these investigations are pending, morphology sup-
plemented by immunophenotyping helps in rapid diagno-
sis. In our case, although morphology was connotative of 
APL, flow cytometry indicated otherwise. Based on the 
symptoms, clinical presentation and deranged coagulation 
profile we still started ATRA and received conformation 
48  hours later of APL though genetic analysis. This case 
consolidates the fact that with the advent of sophisticated 
automated diagnostic analyzers, morphological examina-
tion that is human eye dependent remains to be the back-
bone in leukemia diagnosis.
4 |  CONCLUSION
In rare cases, APL can present with HLD-DR and CD34-
positive immunophenotype. With a strong index of suspicion 
along with classical clinical and morphological findings, 
ATRA should be started in such patients while molecu-
lar analysis results are awaited. Although rarely reported, 
HLA-DR and CD34-positive cases present with high white 
blood cell count making them susceptible to increased induc-
tion mortality.
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